NVAX

Novavax

NVAX

Attention (50-day avg)0.02%

Attention rank (50-day avg)#281

Bullish sentiment (50-day avg)74%

Price to earnings ratio3.63

Market capitalization1.8B

Earnings per share-1.55

Dividend yield (TTM)—

Revenue (annual)1.1B

Net income (annual)440.3M

Social

What share of all stock conversation is about NVAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.06% +0.01	0.03% +0	0.02% +0.01	0.01% -0.04

Sep 29

The short interest in NVAX has increased to 49.9M, representing 35% of the float and 12.4 days to cover.
Novavax's Matrix-M platform may have a competitive advantage due to its ability to elicit mucosal immunity, making it a potential blockbuster vaccine.
The hiring of a Head of U.S. COVID Franchise at Sanofi is seen as a leading indicator for the future of the combination vaccine, potentially signaling a shift from lab to launch.

Generated by AI

Sentiment

Of the messages about NVAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	68.35% -22.9	76.98% -3.5	75.03% +7.68	68.07% -4.76
Bearish	31.65% +22.9	23.02% +3.5	24.97% -7.68	31.93% +4.76

Bullish· Sep 29

The short interest in NVAX has increased, reaching 31.8% of the float, making it difficult for shorts to cover their positions.
NVAX has been holding well against rising treasury yields and global uncertainty, with a strong physical corporate landscape and upcoming pandemic stockpile RFP window locking in massive federal allocations.
The company's unique position as the only real COVID vaccine with a real malaria vaccine and the best flu vaccine has the potential to drive its share price to 25x or even 50x.

Bearish· Sep 29

The company's stock price is vulnerable to margin calls, as 56% of stocks are below their 200-day average and 73% are below their 50-day average.
The convertible debt is seen as a dam holding the share price back, waiting for the floodgates to open when enough pressure builds.
The company's COVID-19 vaccine, Nuvaxovid, is criticized for being less favored by the FDA compared to Moderna's products, leading to a negative perception of the company.

Generated by AI

Topics

Of the messages about NVAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	92.68%	68.91%	42.22%	48.21%
Technical Analysis	7.32%	26.59%	42.1%	28.62%
Earnings	0%	3.75%	1.35%	8.78%
Analysts	0%	0%	6.76%	7.12%
Macro	0%	0.75%	6.76%	5.13%
Controversies	0%	0%	0.8%	2.14%

Earnings· Aug 6

Novavax reported Q2 2026 earnings with revenue of $57M, beating estimates by 8%, and EPS of -$0.32, beating estimates by 13.5%.
The company maintained FY2026 guidance and highlighted upcoming partner milestones, including a $75M milestone with Sanofi for the COVID-19-Influenza Combination trial.
Novavax raised its full-year revenue guidance to $235M-$275M, excluding supply sales, milestone payments, and royalties linked to the Sanofi deal.

Analysts· Aug 20

Bank of America analyst downgraded Novavax to Underperform with a price target of $7, citing growth uncertainties and a restricted US label.
Other analysts, including BTIG, H.C. Wainwright, and Jefferies, are more bullish on Novavax, projecting massive upside potential of up to 162%.
Refinitiv/Verus upgraded Novavax from SELL to BUY, while Bank of America and Citi have maintained bearish ratings, highlighting a divergence in analyst opinions on the stock.

Announcements· Sep 28

Novavax's Matrix-M adjuvant significantly boosts the body's immune response against cancer and promotes strong antibody and T-cell responses, making it a promising tool in oncology.
Novavax's Nuvaxovid vaccine has been approved in the US, EU, and Japan, and is being commercialized by Sanofi, with Novavax receiving a royalty on every dose sold.
The US government is on track to announce new contract awards for the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program, with Sanofi and Novavax being favored due to their traditional and protein-based vaccine platforms.

Controversies· Nov 11

The US FDA has removed the clinical hold on Novavax's COVID-19-Influenza Combination (CIC) and standalone flu vaccine Phase 3 trials.
Novavax has provided additional data showing that a serious adverse event, initially reported as motor neuropathy and later updated to amyotrophic lateral sclerosis (ALS), was not related to the vaccine.
The FDA has cleared Novavax to resume Phase 3 trial enrollment, with the company aiming to start trial activities promptly with support from clinical investigators and partners.

Macro· May 6

The WTO proposal to waive patent rights for COVID-19 vaccines may take months to be adopted, and even then, it may not address the main barriers to expanding vaccine manufacturing, such as trade secrets, know-how, and scarce physical supplies.
The US government's decision to support the proposal may set a precedent that could discourage healthcare companies from investing in research and development, potentially leading to fewer life-protecting medicines in the coming years.
Many experts believe that the main bottleneck in expanding COVID-19 vaccine production is not access or patents, but rather the lack of vials, raw materials, and manufacturing capacity, and that subsidies for vaccine makers or aid to companies with manufacture and supply/distribution issues may be more effective solutions.

Technical Analysis· Feb 26

$NVAX is expected to squeeze to $25 resistance after a sell spike.
The stock has broken out of an inverted H&S continuation pattern, indicating significant upside ahead.
Buyers are defending pullbacks, and the trend is still intact, with the stock due for another run.

Generated by AI

Community

Of the messages about NVAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.09%	94.49%	90.6%	86.05%
Newcomers	2.91%	5.51%	9.4%	13.95%

Regulars· Sep 29

The short interest in Novavax (NVAX) has increased, with 35% of the float available for shorting and 12.4 days to cover, which could lead to a short squeeze.
Novavax's Matrix-M vaccine has the potential to be a blockbuster, with its unique subunit protein platform allowing for mucosal immunity and its potential to be used against respiratory viruses and mucosal tissue, including the colon.
The hiring of a Head of U.S. COVID Franchise at Sanofi, which is overseeing the commercial strategy for a combination vaccine featuring Novavax's asset, could signal a critical shift in the project's timeline, potentially leading to a Phase 3 trial.

Newcomers· Sep 29

The newcomer is optimistic about NVAX's potential, suggesting a breakout in 2024, and believes the current price range (6.1-10.3) is a "buying zone" where the stock can accumulate.
The pressure on many stocks, including NVAX, due to margin calls and forced selling, has led to a significant number of stocks trading below their 50- and 200-day averages.
The newcomer is extremely bullish on NVAX, calling it a "rocketship" and predicting a surge to $100+ in a single trading day, citing the company's focus on oncology as a key factor in its potential success.

Generated by AI

News

Novavax Inc. stock outperforms competitors on strong trading day

1d agoMarketWatch

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Novavax (NVAX) stood at $10.79, denoting a +1.53% move from the preceding trading day.

1d agoYahoo Finance UK

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

2d agoYahoo Finance UK

Novavax Inc. stock underperforms Wednesday when compared to competitors

6d agoMarketWatch

Novavax Inc. stock outperforms competitors on strong trading day

7d agoMarketWatch

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Tipranks Press Release.

8d agoThe Globe and Mail

Also Discussed

Investors talking about NVAX also mention

#	Name	Attention
1	Moderna Inc.MRNA	0.1%+0.03
2	BioNTech SEBNTX	0%+0
3	CVAC - CureVac N.V.	——
4	Inovio Pharmaceuticals Inc.INO	0%+0
5	VXRT - Vaxart, Inc.	——
6	Pfizer Inc.PFE	0.04%-0.01
7	Sanofi ADRSNY	0%-0.01
8	Nanoviricides Inc.NNVC	0%0
9	Vir Biotechnology, Inc.VIR	0%+0
10	Co-Diagnostics Inc.CODX	0%+0

Novavax Inc.

Healthcare
Biotechnology

Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases. Novavax Inc. uses a proprietary recombinant protein platform paired with its Matrix-M adjuvant technology to support immune responses across its vaccine portfolio. Its current products and programs include COVID-19 vaccines marketed under the Nuvaxovid brand and the R21/Matrix-M malaria vaccine, along with research efforts aimed at additional infectious disease targets. The company serves global public health markets through vaccine development, manufacturing, and commercialization activities, and it also works with partners and institutions involved in vaccine supply and distribution. Headquartered in Gaithersburg, Maryland, Novavax Inc. remains recognized for its vaccine-focused business model and its role in advancing protein-based immunization technologies.

Website

Location

21 Firstfield Road

Gaithersburg, MD, 20878

United States

Social

What share of all stock conversation is about NVAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.06% +0.01	0.03% +0	0.02% +0.01	0.01% -0.04

Sep 29

The short interest in NVAX has increased to 49.9M, representing 35% of the float and 12.4 days to cover.
Novavax's Matrix-M platform may have a competitive advantage due to its ability to elicit mucosal immunity, making it a potential blockbuster vaccine.
The hiring of a Head of U.S. COVID Franchise at Sanofi is seen as a leading indicator for the future of the combination vaccine, potentially signaling a shift from lab to launch.

Generated by AI

Sentiment

Of the messages about NVAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	68.35% -22.9	76.98% -3.5	75.03% +7.68	68.07% -4.76
Bearish	31.65% +22.9	23.02% +3.5	24.97% -7.68	31.93% +4.76

Bullish· Sep 29

The short interest in NVAX has increased, reaching 31.8% of the float, making it difficult for shorts to cover their positions.
NVAX has been holding well against rising treasury yields and global uncertainty, with a strong physical corporate landscape and upcoming pandemic stockpile RFP window locking in massive federal allocations.
The company's unique position as the only real COVID vaccine with a real malaria vaccine and the best flu vaccine has the potential to drive its share price to 25x or even 50x.

Bearish· Sep 29

The company's stock price is vulnerable to margin calls, as 56% of stocks are below their 200-day average and 73% are below their 50-day average.
The convertible debt is seen as a dam holding the share price back, waiting for the floodgates to open when enough pressure builds.
The company's COVID-19 vaccine, Nuvaxovid, is criticized for being less favored by the FDA compared to Moderna's products, leading to a negative perception of the company.

Generated by AI

Topics

Of the messages about NVAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	92.68%	68.91%	42.22%	48.21%
Technical Analysis	7.32%	26.59%	42.1%	28.62%
Earnings	0%	3.75%	1.35%	8.78%
Analysts	0%	0%	6.76%	7.12%
Macro	0%	0.75%	6.76%	5.13%
Controversies	0%	0%	0.8%	2.14%

Earnings· Aug 6

Novavax reported Q2 2026 earnings with revenue of $57M, beating estimates by 8%, and EPS of -$0.32, beating estimates by 13.5%.
The company maintained FY2026 guidance and highlighted upcoming partner milestones, including a $75M milestone with Sanofi for the COVID-19-Influenza Combination trial.
Novavax raised its full-year revenue guidance to $235M-$275M, excluding supply sales, milestone payments, and royalties linked to the Sanofi deal.

Analysts· Aug 20

Bank of America analyst downgraded Novavax to Underperform with a price target of $7, citing growth uncertainties and a restricted US label.
Other analysts, including BTIG, H.C. Wainwright, and Jefferies, are more bullish on Novavax, projecting massive upside potential of up to 162%.
Refinitiv/Verus upgraded Novavax from SELL to BUY, while Bank of America and Citi have maintained bearish ratings, highlighting a divergence in analyst opinions on the stock.

Announcements· Sep 28

Novavax's Matrix-M adjuvant significantly boosts the body's immune response against cancer and promotes strong antibody and T-cell responses, making it a promising tool in oncology.
Novavax's Nuvaxovid vaccine has been approved in the US, EU, and Japan, and is being commercialized by Sanofi, with Novavax receiving a royalty on every dose sold.
The US government is on track to announce new contract awards for the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program, with Sanofi and Novavax being favored due to their traditional and protein-based vaccine platforms.

Controversies· Nov 11

The US FDA has removed the clinical hold on Novavax's COVID-19-Influenza Combination (CIC) and standalone flu vaccine Phase 3 trials.
Novavax has provided additional data showing that a serious adverse event, initially reported as motor neuropathy and later updated to amyotrophic lateral sclerosis (ALS), was not related to the vaccine.
The FDA has cleared Novavax to resume Phase 3 trial enrollment, with the company aiming to start trial activities promptly with support from clinical investigators and partners.

Macro· May 6

The WTO proposal to waive patent rights for COVID-19 vaccines may take months to be adopted, and even then, it may not address the main barriers to expanding vaccine manufacturing, such as trade secrets, know-how, and scarce physical supplies.
The US government's decision to support the proposal may set a precedent that could discourage healthcare companies from investing in research and development, potentially leading to fewer life-protecting medicines in the coming years.
Many experts believe that the main bottleneck in expanding COVID-19 vaccine production is not access or patents, but rather the lack of vials, raw materials, and manufacturing capacity, and that subsidies for vaccine makers or aid to companies with manufacture and supply/distribution issues may be more effective solutions.

Technical Analysis· Feb 26

$NVAX is expected to squeeze to $25 resistance after a sell spike.
The stock has broken out of an inverted H&S continuation pattern, indicating significant upside ahead.
Buyers are defending pullbacks, and the trend is still intact, with the stock due for another run.

Generated by AI

Community

Of the messages about NVAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.09%	94.49%	90.6%	86.05%
Newcomers	2.91%	5.51%	9.4%	13.95%

Regulars· Sep 29

The short interest in Novavax (NVAX) has increased, with 35% of the float available for shorting and 12.4 days to cover, which could lead to a short squeeze.
Novavax's Matrix-M vaccine has the potential to be a blockbuster, with its unique subunit protein platform allowing for mucosal immunity and its potential to be used against respiratory viruses and mucosal tissue, including the colon.
The hiring of a Head of U.S. COVID Franchise at Sanofi, which is overseeing the commercial strategy for a combination vaccine featuring Novavax's asset, could signal a critical shift in the project's timeline, potentially leading to a Phase 3 trial.

Newcomers· Sep 29

The newcomer is optimistic about NVAX's potential, suggesting a breakout in 2024, and believes the current price range (6.1-10.3) is a "buying zone" where the stock can accumulate.
The pressure on many stocks, including NVAX, due to margin calls and forced selling, has led to a significant number of stocks trading below their 50- and 200-day averages.
The newcomer is extremely bullish on NVAX, calling it a "rocketship" and predicting a surge to $100+ in a single trading day, citing the company's focus on oncology as a key factor in its potential success.

Generated by AI

Novavax

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 6

Analysts· Aug 20

Announcements· Sep 28

Controversies· Nov 11

Macro· May 6

Technical Analysis· Feb 26

Regulars· Sep 29

Newcomers· Sep 29

Novavax Inc. stock outperforms competitors on strong trading day

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax Inc. stock underperforms Wednesday when compared to competitors

Novavax Inc. stock outperforms competitors on strong trading day

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Also Discussed

Novavax Inc.

Company Information

Location

Novavax Inc. stock outperforms competitors on strong trading day

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax Inc. stock underperforms Wednesday when compared to competitors

Novavax Inc. stock outperforms competitors on strong trading day

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 6

Analysts· Aug 20

Announcements· Sep 28

Controversies· Nov 11

Macro· May 6

Technical Analysis· Feb 26

Regulars· Sep 29

Newcomers· Sep 29